Want to join the conversation?
Global pharmaceutical giant $ABBV announced that its product candidate for treatment of rheumatoid arthritis, selective JAK1 inhibitor ABT-494, has successfully achieved its primary endpoint in two Phase 2 studies."We are encouraged by Phase 2 results & we'll advance ABT-494 to Phase 3 studies with once-daily formulation," said Mike, EVP R&D & CSO.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th